Exhibitors

BOOTH 1: Metrum Institute/Metrum Research Group
BOOTH 2: Simcyp
BOOTH 3: ICON Development Solutions
BOOTH 4: Pharsight
BOOTH 5: Pirana
BOOTH 6: Archimedes
BOOTH 7: Bayer Technology Services
BOOTH 8: GVK Biosciences
BOOTH 9: Simulations Plus
BOOTH 10: The AEgis Technologies Group
BOOTH 11: American College of Clinical Pharmacology (ACCP)
BOOTH 12: AstraZeneca
BOOTH 13: American Society of Pharmacometrics (ASoP)
BOOTH 14: Mathworks
BOOTH 15: PLTsoft
BOOTH 16: Mango Solutions

 

BOOTH 1: Metrum Institute/Metrum Research Group

     

Metrum Institute is a not for-profit organization dedicated to solving unmet needs in biomedical research through quantitative modeling and simulation. Our efforts include applied academic research, training, education, resource sharing, and research and development efforts focused on new open-source tools and methods. For more info visit: www.metruminstitute.org.

Metrum Research Group provides contract services aimed at catalyzing biomedical R&D through quantitative modeling and simulation. Our collaborations with the pharma/biotech industry are characterized by cutting-edge science, transfer of knowledge, quality deliverables and innovative, strategic application of modeling and simulation technologies. We've recently applied our therapeutic area modeling and simulation expertise to develop METAMODL, a subscription-based library of therapeutic area disease progression models and public source data sets. For more info visit: www.metrumrg.com and www.metamodl.com. 

BOOTH 2: Simcyp

Simcyp develops innovative modelling and simulation tools which are used by the majority of the world’s leading pharmaceutical companies. The Simcyp Consortium, which includes the top ten global pharmaceutical companies, brings together experts to guide research and development at the company, ensuring the products offered continue to meet, and exceed, industry standards. Simcyp’s products and services are used world-wide by industry, regulatory bodies and academic centres of excellence. The research and development team comprise experts in the areas of paediatrics, drugs metabolism, transporters, pharmacodynamics and physiologically-based pharmacokinetics and continuously support users of the Simulator. Services and support offered by Simcyp include:

The Simcyp Simulator
The Simcyp Population-based Simulator streamlines drug development through the modelling and simulation of pharmacokinetics and pharmacodynamics in virtual populations and is the industry’s most sophisticated platform for the prediction of drug-drug interactions and pharmacokinetic outcomes in clinical populations. The Simulator has been used to provide key information for regulatory submissions and management decisions relating to clinical trial design and avoidance along with drug-drug interaction information.

Simcyp Paediatric
Simcyp Paediatric enables user to model pharmacokinetic behaviour in infants, neonates and children which addresses problematic areas of drug development in this population. Users are able to gain valuable information relevant to first-time dosing decisions and the design of clinical studies.

Simcyp Animal
The recently expanded Simcyp Animal Simulator incorporates two animal models – Simcyp Rat and Simcyp Dog. The research and development team at Simcyp are also finalising a new Mouse Model to be incorporated into Simcyp Animal. Simulations with the models can help users understand the behaviour of their drugs and have been used to increase confidence in in vitro – in vivo extrapolation (IVIVE) before moving to human simulations. Simcyp Dog can help to assess the likelihood of observing food effects for orally dosed drugs.

Simcyp Consultancy
Consortium members and non-members can tap into Simcyp science through Simcyp Consultancy Services. This provides hands-on data analysis, data interpretation, report writing and guidance in regulatory submissions.  

Simcyp Workshops
Simcyp runs educational hands-on workshops around the world every year to provide essential support for users of the Simulator. The intensive courses entitled ‘Model-based drug development: Incorporating population variability into mechanistic prediction of PK and modelling of PK-PD’ always prove to be extremely popular and bring together scientists from academia, industry and regulatory bodies.

Simcyp Training
Simcyp Training offers practical support for new users to the simulator and serves as a refresher to more experienced users. The focus of the training is on the mechanics of operating Simcyp and has proved extremely beneficial in training large groups of users.

Simcyp Academic License
Simcyp grants licenses for the Simulator to academic centre of excellence in research related to drug development. Currently over 60 institutions world-wide are benefiting from the same advances tools that are used by the industry. Academic agreements differ from Consortium member contracts to reflect the not-for-profit nature of the research.

Full details on all the services offered by Simcyp and information on the activities of the research and development team at the company can be found on our website - www.simcyp.com

BOOTH 3: ICON Development Solutions

ICON Development Solutions specializes in the strategy and delivery of early-phase clinical development services to enable informed, timely decision making for our clients. With global clinical pharmacology and bioanalytical capabilities, ICON offers industry-leading solutions in early-phase clinical research, bioanalytical/immunoassay, biomarkers, PK/PD modeling & simulation and the full range of support services. Our multi-disciplinary experts incorporate scientific excellence and product development strategy in all that we do -- with the experience to address the most demanding drug development challenges with an unyielding focus on completing clinical studies on time, on budget and with the quality that will withstand the most vigorous scrutiny.

ICON Development Solutions supports the development of NONMEM®, the Software that has facilitated the analysis of data for pharmaceutical research and development for the last 30 years; the Gold Standard for population Pharmacokinetic / Pharmacodynamic analysis.

The present version, NONMEM® 7.1.2 is the only program that offers all of these methods under one roof:

  • FO
  • FOCE
  • ITS
  • Importance Sampling EM
  • SAEM
  • MCMC Bayesian Analysis

Other enhancements found in NONMEM® 7.1.2 include: Improved incidence of completion when using the multiple problem feature; three stage hierarchical Markov Chain Monte Carlo (MCMC) methods; improved efficiency and incidence of success in problems using the classical NONMEM® method and many more that you will get to experience with your new software. NONMEM® 7.1.2 also provides a comprehensive tool-kit in an easier to use package to facilitate population-based data analyses, and improves the rate of success of analyzing complex PK/PD models.

NONMEM® is an evolving program, reflecting tested methodological and programming improvements.  The latest version of NONMEM®, 7.2, will have the following additional features:

  • Parallel computing of a single problem over multiple cores or computers.  The computation of a single problem that can take many hours or days may be distributed over two or more cores and/or computers to complete in a shorter time.
  • Memory dynamically allocated according to problem size.  No need to recompile the NONMEM program for unusually large problems.  Memory is automatically sized according to the number of parameters and number of subjects. User may override program generated suggested values using a statement in the control stream. Often for moderate sized problems, this results in much smaller memory usage, compared to the standard memory usage in NONMEM 7.1.2 and earlier.  Particularly helpful for parallel computing when using multiple cores on a single computer.
  • Control stream files may be written in mixed case
  • Variance matrix parameters are output in covariance and correlation format
  • Variance matrix parameters may be input in covariance, correlation, or Choleksy format
  • XML markup version of the NONMEM report file
  • Features to facilitate stochastic differential equations (SDE)

For sales and licensing information, please visit www.iconplc.com/technology/products

BOOTH 4: Pharsight

Pharsight (www.pharsight.com) software products and services facilitate improved productivity and strategic decision making in drug development. Since the company's founding in 1995, our goal remains to help customers reduce the time, cost and risk of drug development. With more than 1200 customers worldwide, Pharsight products and services are used by all of the world's top 50 drug development organizations.

Pharsight software is also provided to the FDA's Center for Drug Evaluation and Research under a Cooperative Research and Development Agreement (CRADA). Under the CRADA, FDA has access to Pharsight software to review clinical trial data, notably for clinical pharmacology and clinical safety reviews.

We are proud to announce the latest release of Phoenix®, our desktop software platform that supports model-based drug development and its utility in translational science.

Phoenix® WinNonlin® is the next generation of Pharsight's industry standard software for PK/PD modeling and noncompartmental analysis. Phoenix® NLME™ provides powerful new data processing and modeling tools for population PK/PD analysis. Phoenix® Connect™ integrates applications built on the Phoenix platform with commonly used third-party analysis and modeling tools such as NONMEM®, R®, SAS®, XPose, PsN, and S-PLUS®.

Pharsight Consulting Services is the world's largest and most experienced pharmacometric consulting group. We are a global team of experts dedicated to supporting strategic development decisions and submission-ready analyses.

Pharsight's staff of more than 40 scientists applies quantitative modeling and simulation to guide critical drug positioning, program strategy and clinical trial design decisions from pre clinical to post-launch. The group's collective experience spans all major therapeutic areas, more than 80 disease indications, and 130 drug classes. Pharsight staff leverages expertise in our leading software tools and in the disciplines of pharmacology, drug and disease modeling, biostatistics, strategic decision-making and regulatory strategy. 

BOOTH 5: Pirana

Pirana (www.pirana-software.com) is a flexible modeling environment for NONMEM and PsN. 'Flexible' means that Pirana can be easily adapted to different modeling setups, and extended using R-scripts.

Why use Pirana?
Use Pirana if you are looking for a user friendly modelling environment from which you can create, run, manage and evaluate models and output, with optimal flexibility and customization features.

  • Suitable for novice and advanced users
  • Supports nmfe, PsN and WFN
  • Define your own editor and other auxiliary software
  • Post-processing scripts: use predefined R or Xpose scripts, or create your own

Pirana main features:

  • Use NONMEM: Manage multiple NONMEM installations, run models using nfme
  • Use the PsN toolkit: execute models and use all other toolkit features
  • Use cluster infrastructures: SGE, MOSIX, as well as all clusters supported by PsN
  • Manage projects, models, results: Manage multiple modeling projects. View run record listed by run number or as hierarchical tree. Add notes and color coding to your models and results. Open and edit control streams with your favorite code editor, or with the built-in model editor. Duplicate models (update table number, use final parameter estimates in new model file), or create new ones based on templates. Browse datasets, tab-files and Xpose files and edit them with your favorite spreadsheet app, text editor or R.
  • Generate output: Generate HTML-summaries from NONMEM run output. Plot and explore datasets or table output files in the Data Inspector. Run custom R scripts on model output (e.g. goodness of fit plots, VPCs etc). Pirana is already bundled with many useful R scripts. The complete Xpose4 menu is available from Pirana as R-scripts.

BOOTH 6: Archimedes

Archimedes Inc. is a healthcare modeling company located in San Francisco. Founded by David Eddy, MD, PhD, pioneer in evidence-based decision making, its technology—the Archimedes Model—is a carefully validated simulation model of health and healthcare. The Model allows clients to simulate clinical trials, perform complex health economics and outcomes research, and assist with portfolio strategy to:

  • Answer questions about efficacy, costs and target markets
  • Create evidence and prove the value of products
  • Determine which treatments have the greatest efficacy
  • Lower the risk of failure of clinical trials

The Archimedes Model is written at a high level of detail using object-oriented programming and runs on a distributed computing network. At its core are hundreds of ordinary and differential equations that represent human physiology and the effects of diseases. The Model also includes detailed aspects of healthcare systems to analyze downstream clinical events, utilization, and costs.

The Model is validated by simulating clinical trials and comparing the results against the results of the actual trial in the real world. To date, more than 50 landmark clinical trials have been used to validate the Model.

The Model has been used by companies such as Eli Lilly, Myriad Genetics, GSK, as well as the CDC, the American Diabetes Association, and Kaiser Permanente to produce substantial savings, improved healthcare, increased revenues, and faster time to market (for more information: www.archimedesmodel.com/case-studies.html).

The Archimedes Model will give you answers to questions that would be impossible to find through evaluation studies or clinical trials.

BOOTH 7: Bayer Technology Services

To gain comprehensive understanding about biological systems, their interaction with pharmaceuticals and the complex dynamical processes involved, Bayer Technology Services relies on mechanistic modeling.

With the aim of supporting decision making along the pharma research and development process, we offer software products for predictive simulation of drug behavior and modeling of cellular pathways as well as professional consulting services, integrating many years of in-house and external market experience.

The Bayer Technology Services (BTS) software products are fully integrated into one Computational Systems Biology Software Suite, representing a user-friendly and flexible software package:

  • PK-Sim® The comprehensive software tool for whole-body physiologically based pharmacokinetic modeling.
  • MoBi® The systems biology software tool for multi-scale physiological modeling and simulation.
  • MoBi® Toolbox for MATLAB® The advanced tool integrating multi-scale physiological modeling and simulation with technical computing.
  • MoBi® Toolbox for R The advanced tool integrating multi-scale physiological modeling and simulation with statistical computing.

Making use of our unique software platform and our outstanding experience applied in a large number of projects in a wide range of fields, Bayer Technology Services (BTS) efficiently executes consulting projects in pharmaceutical research and life sciences. 

BOOTH 8: GVK Biosciences

GVK Biosciences (GVK BIO) is Asia’s leading Discovery Research and Development organization. GVK BIO provides a broad spectrum of services, stand-alone and integrated, across the R&D value chain. Our discovery services consist of Chemistry, Biology and Informatics; the development services include Clinical research, Clinical pharmacology and Process R&D. GVK BIO’s diverse portfolio of more than 150 customers includes big Pharma, leading biotech, agro, life-sciences companies and topnotch academic institutions.

To assist Model-Based meta-analysis (MBMA) programs, GVK BIO has collaborated with Quantitative Solutions, a scientific consultancy to the pharmaceutical and biotech industry, to offer Clinical Outcomes Databases for a number of therapeutic areas/indications along with customization services to suite specific modeling needs. To date QS-GVK BIO offer about 10 Databases (given below) that are model ready and available off the shelf. The database coverage will be expanded to include Oncology indications very soon.

  • Model Ready Databases – Indications covered: RA, HCV, Pain, Depression, Osteoporosis, Schizophrenia, Alzheimer’s, Dyslipidemia, Diabetes, Glaucoma
  • The databases and models derived from them can be used to characterize the probability distribution of clinical efficacy and tolerability as a function of various treatment and patient factors.
  • They can help companies conduct comparative efficacy and safety analysis, link/scale biomarkers to clinical outcomes, predict/improve trial outcome, and develop product differentiation strategies.

Over the past 5 years in our Custom Development Services, GVK BIO has covered more than 56 indications that have been developed to meet specific modeling needs of our big Pharma customers, as we work with all the major Pharma companies.

GVK BIO provides premier quality customized services and has proven effective as accredited by

  • Novartis accredits "The partnership with GVK Bio for data extraction and populating the spreadsheet has been established and has proved very effective" - Population Approach Group Europe (PAGE), June 23-26, 2009.

GVK BIO is also developing an Infrastructure to host publicly available and proprietary clinical trial outcome databases, in a unified schema and provide an online web based access to search, query and export the results to be imported in a CSV format to be readily used in Microsoft based M&S Tools. 

BOOTH 9: Simulations Plus

Simulations Plus is a leading provider of consulting services and modeling & simulation software for pharmaceutical discovery and development.

ADMET Predictor™ is a computer software program for advanced predictive modeling of numerous vital ADME-Tox properties from molecular structures, including physicochemical endpoints, multiple toxicities, metabolic activities, and sites of metabolism. Additionally, via its integrated ADMET Modeler™ module, it is also capable of building predictive models of new properties from your data.

MedChem Studio™ is an intuitive cheminformatics platform supporting lead identification and prioritization, de novo design, scaffold hopping and lead optimization.  Quite simply, it is the industry's most advanced data mining and drug design software for medicinal chemists.

MedChem Designer™ combines innovative molecule drawing features with a few free fast and accurate ADMET property predictions from our top-ranked ADMET Predictor™. Chemists who design new compounds for pharmaceutical, cosmetic, industrial chemical, herbicide, pesticide, and food applications will enjoy the highly intuitive interface with a number of convenience features and capabilities not available in other molecule drawing software.

DDDPlus™ is the industry’s only in vitro dissolution software for the formulation scientist that models and simulates the in vitro dissolution of active pharmaceutical ingredients (API) and formulation excipients dosed as powders, capsules, tablets, and swellable or non-swellable polymer matrices under various experimental conditions.

GastroPlus™ is an advanced software program that simulates the absorption, pharmacokinetics, and pharmacodynamics for drugs administered via the intravenous, oral, oral cavity, ocular, and pulmonary routes in human and preclinical species. Since 1997, Simulations Plus has evolved GastroPlus to a high state of refinement, providing the industry's most accurate, flexible, and powerful simulation program.

Benefits of GastroPlus: 

  • Predict steady-state and dynamic drug-drug interactions (DDI)
  • Virtual absorption screening of drug candidates in animals and human
  • Understand food effects
  • Predict first-in-human/animal doses through PBPK simulation
  • Conduct virtual population studies
  • Fit complex nonlinear metabolism and transport in any tissue
  • Build PBPK/PD models with target tissue concentrations
  • Track multiple metabolites (and metabolites of metabolites)
  • Deconvolute in vivo dissolution for IVIVC

Web: www.simulations-plus.com

BOOTH 10: The AEgis Technologies Group

AEgis Technologies is pleased to provide modeling and simulation software tools, support, training and consulting services to scientists working in pharmaceutical and toxicological research around the world.  AEgis’ family of software tools for PK/PD/PBPK modeling and computational biology includes acslX and ADME Workbench™.

For over 30 years, acslX and its predecessor ACSL have provided scientists and engineers with a powerful and flexible software environment for modeling, simulation and analysis of complex nonlinear systems and data.  Today, acslX is used in a diverse range of applications in biological modeling, including: classical compartmental PK/PD, physiologically-based PK, population PK/PD, disease modeling, systems biology, virtual tissues and organs, and IVIVE.

Starting in Spring 2011, AEgis is pleased to introduce a new tool which builds on the acslX computational engine: ADME Workbench.  ADME Workbench is a versatile software tool providing flexible, robust pharmacokinetic modeling by integrating state-of-the-art ADME prediction methods.  Designed for business and research applications in toxicology and pharmacology, ADME Workbench supports prediction from available in vitro and/or in vivo data for drugs and environmental chemicals. The ADME Workbench user interface offers a highly optimized workflow for predictive pharmacokinetics, while allowing lots of flexibility to adapt to your needs:

  • Support for several state-of-the-art PK prediction techniques, including whole-body and lumped physiologically-based pharmacokinetic (PBPK) models, and Wajima’s allometry.
  • PBPK models which include advanced GI uptake models, support for both linear and nonlinear kinetics, and an advanced liver model.
  • Support for end-user customization of any of the provided PBPK models.
  • A choice of prediction methods depending of the availability of preclinical data either determined in vitro and/or in vivo in single or multiple species.
  • Ability to integrate values of ADME parameters predicted from a broad range of methods.
  • Ability to simulate a single compound or multiple compounds in batch mode.
  • Support for simulation of drug-drug interactions (DDI) using traditional or advanced gut and liver models.
  • Simulation of tissue concentration at the macro (whole organ) and micro (cell, interstitial fluid) levels either for the bound or unbound drug condition.
  • Ability to define a variety of target species and populations for prediction.
  • Ability to perform reverse calculation of external dose from user specified target AUC and Cmax, for example.
  • Curve shape and predictive quality assessment, accomplished via the use of several statistical parameters and determination of a global degree of accuracy for the shape of the curve of the predicted plasma concentration-time profile.

No black-box proprietary models, no one-size-fits-all prediction methods, no prohibitively high license fees.  Just versatile, powerful pharmacokinetic prediction that adapts to your needs.

AEgis Technologies is pleased also offer world-class modeling and simulation support, training and consulting services to scientists working in pharmaceutical and toxicological research.

More information about acslX and ADME Workbench are available at www.acslX.com, 800-647-ACSL or [email protected].

BOOTH 11: American College of Clinical Pharmacology (ACCP)

The American College of Clinical Pharmacology (ACCP) is a non-profit organization comprised of a wide spectrum of health care professionals devoted to improving health by optimizing therapeutics and providing innovative leadership and interdisciplinary education that will enable the generation, integration and translation of scientific knowledge to optimize research, development and utilization of medication for the benefit of all. Visit us at www.ACCP1.org to learn more.

Boasting a rich 40-year history, the American College of Clinical Pharmacology (ACCP) has a diverse global membership of healthcare professionals dedicated to improving health by optimizing therapeutics.  ACCP is one of the few organizations to still offer continuing medical education (CME) credits and continuing education units (CEU) for qualified professionals.  Individuals can participate in meetings or online educational workshops and symposia on cutting-edge, relevant topics related to clinical pharmacology and the optimal use of therapeutics.  These interactions provide a forum for new scientific ideas and bring together healthcare professionals of various disciplines to meet and discuss areas of common interest. In addition to the commitment to continuing education, collegial exchange and networking opportunities, ACCP publishes The Journal of Clinical Pharmacology and will soon launch an eJournal, Clinical Pharmacology in Drug Development, both are provided to its Members at no additional cost.  Join ACCP Today!

BOOTH 12: AstraZeneca

AstraZeneca Pharmacueticals LP

We are one of the world's leading biopharmaceutical companies, with more than 62,000 people working across six continents. Ours is a business that brings together an amazing diversity of talents, perspectives and specialist backgrounds. But we are all united by one compelling vision: to create the most innovative and effective treatments for the world’s most serious illnesses.

Right Dose, Right Schedule, Right Drug

Model-based drug development – applying predictive science

At AstraZeneca, we’re spearheading a revolutionary approach to drug research and development. In our mission to bring life-changing medicines to the global population, we’re heavily investing into Predictive Sciences – so we can tackle illness and disease.

We’re seeking experienced modellers with mathematical, statistical and analytical expertise, to work on major, high profile projects from early drug discovery through clinical development, to market launch.

We’re at the vanguard of drug research and development, producing new medicines designed to improve the health and quality of life of patients around the world – as well as focusing on getting the best from every medicine we make. But as always, we’re looking to improve. We want to be able to predict outcomes, streamline our drug discovery and development, and identify the most promising projects more quickly. So as a modeller, you’ll collaborate with a multidisciplinary team to develop and implement quantitative pharmacokinetic/ pharmacodynamic data models, to aid in understanding drug disposition, target prioritisation, therapeutic modality selection, lead optimisation, biomarker characterisation and early clinical trial design.

And right now is an exceptional time to join, as Predictive Science is taking centre stage in our R&D process. You’ll make an impact from day one by contributing to the quantitative understanding of the efficacy and safety of molecules. And working in partnership with experts across both academia and industry, you’ll obtain maximum recognition for your innovation and successes.

The opportunities to progress are significant too, as we’re committed to investing in and developing talent. Please visit www.astrazenecacareers.com for more information on AstraZeneca and to view our current openings.

BOOTH 13: American Society of Pharmacometrics (ASoP)

The vision of the American Society of Pharmacometrics (ASoP) is to promote and advance the discipline of Pharmacometrics, through INTEGRATION, INNOVATION, and IMPACT

ASoP’s mission is

  • to serve as the sponsoring organization for ACoP
  • to offer a central organization for the integration of pharmacometrics communities, initiatives, consortia, and educational activities
  • to partner with other scientific and medical organizations
  • to provide resources, mentoring, leadership opportunities, and educational services, to its members.

ASoP Membership benefits include:

  • Discount on ACoP meetings and ASoP educational activities
  • Access to ASoP directory and career site
  • Many opportunities to participate in ASoP:officer, board member, committee chair, committee member
  • discount on membership fees, educational programs/conferences of other organization (FUTURE)
  • Journal on Pharmacometrics and discount on publishers’ other materials (FUTURE)

If you have questions about ASoP membership or want to share your suggestions for ASoP membership benefits or activities, please contact us at: [email protected].

BOOTH 14: Mathworks

Accelerate control design and system-level analysis with physical system models. Researchers at biotech and pharmaceutical companies use MathWorks products to perform data analysis and modeling throughout drug discovery, development, clinical trials, and manufacturing. MathWorks software provides a flexible, integrated environment spanning application areas that include:

  • Pharmacokinetic and pharmacodynamic (PK/PD) modeling
  • Biological image processing
  • Biostatistics
  • Bioinformatics
  • Biochemical modeling and systems biology
  • Process analytical technology (PAT)

Pharmaceutical researchers at any level of programming expertise can perform analysis, visualization, and modeling using graphical user interfaces (GUIs) and command-line functionality. Scripting facilities enable straightforward automation of computational workflows. For more information visit www.mathworks.com.

BOOTH 15: PLTsoft

PLT Tools, a graphical environment for the NONMEM System, is designed to facilitate all aspects of a NONMEM analysis (with the exception of creation of datafiles).  With PLT Tools, a data analyst can:

  1. Edit control streams using a built-in editor (or access ones preferred editor directly from PLT Tools).  The data analyst can also access a library of control streams.
  2. Edit a Graphics Script: a graphical interface enables the user to customize graphics including all labels, grouping variables, headers, etc.  If the data analyst does not create a Graphics Script, default graphics are created.
  3. Click a button to run NONMEM.  PLT Tools names all documents with a unique timestamp, reformats certain documents in PDF format, and files all documents in a standardized file structure, thereby assuring traceability (Part 11 compliance).
  4. Obtain comprehensive, customizable diagnostics high-resolution graphics.  PLT Tools now includes complete support for xpose.
  5. Obtain fully automated covariate searches, visual predictive checks, likelihood profiles, and bootstrap and jackknife analyses.
  6. Click a button to create a report (RTF format) containing tables / graphics / NONMEM outputs. 
  7. Click a button to bundle all relevant NONMEM outputs and graphics into an archive for regulatory filings.

PLT Tools is the “one-step” application to facilitate conduct of NONMEM analyses.  Visit us at www.PLTsoft.com.

BOOTH 16: Mango Solutions

Mango Solutions is a privately owned software company, who specialise in the delivery of tailored products and solutions for pharmacometric groups.  Mango work with Modeling & Simulation groups from 8 of the top 10 pharmaceutical companies, providing a range of services and software solutions.  The Mango team consists of a unique mixture of software developers and analytical modelers who provide a range of services including:

  • Customised training courses, such as bespoke “R for Pharmacometrics” training
  • Targeted consulting services, such as the generation of simulation routines in order to evaluate adaptive trial design
  • The design and delivery of tailored software systems to support PKPD processes
  • Commercial support of open source softwares used in the PKPD field, such as the R language
  • The delivery of advanced software products that help modelers in their day to day analytic work

For more details of how we help our pharmaceutical customers please visit us at in the Exhibition hall, or go to www.mango-solutions.com